Afficher la couverture 'PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers | Teyssonneau, Diego' en grand format
/5

0 avis

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers

Archive ouverte

Teyssonneau, Diego | Thiery-Vuillemin, Antoine | Dariane, Charles | Barret, Eric | Beauval, Jean-Baptiste | Brureau, Laurent | Crehange, Gilles | Fiard, Gaelle | Fromont, Gaëlle | Gauthe, Mathieu | Ruffion, Alain | Renard-Penna, Raphaele | Mathieu, Romain | Sargos, Paul | Roupret, Morgan | Ploussard, Guillaume | Roubaud, Guilhem

Edité par CCSD ; MDPI -

International audience. Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.

Suggestions

Du même auteur

Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic)

Archive ouverte | Ploussard, Guillaume | CCSD

International audience. Objective Annual countrywide data are scarce when comparing surgical approaches in terms of hospital stay outcomes and costs for radical prostatectomy (RP). We aimed to assess the impact of s...

Perioperative outcomes after radical prostatectomy; does the surgical approach change the impact of hospital volume? A nationwide analysis

Archive ouverte | Baboudjian, Michael | CCSD

International audience

PARP inhibitors in prostate cancers, is it time for combinations?

Archive ouverte | Teyssonneau, Diego | CCSD

International audience. Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disea...

Chargement des enrichissements...